Subject Index

active metabolites 212 Brief Psychiatric Rating Scale (BPRS) adenylate cyclase 82 131 adenylcyclase 9 4-bromo-2,5-dimethoxyphenyliso- adverse drug reactions 238 propylamine 15 AJ76 82 buproprion 174,190 akathesia 138 -, dose-effect relationship 174 akinesia 131 -, prediction of response 174 alcohol abuse 212 buspirone 52 alprazolam 111, 190 amisulpride 70,82 cardiovascular toxicity 163 amitriptyline 149, 163, 199,212,253 carpipramine 82 amperozide 70 chlorpromazine 70,138,199,212,230 amphetamine 124 citalopram 174,190,199 amoxapine 253 clinical response 149,253 anticholinergic effects 163 clomipramine 163, 190, 199,212 antidepressant plasma levels 238 clopenthixol 101 antidepressant, mechanism of action 38 clozapine 52,70,82, 101, 131,212 antidepressants 149, 190, 212, 238, 253 CNS-toxicity 163 antiparkinsonian medication 131 codeine 199 antipsychotic clinical response 138,253 compliance 174 antipsychotic dose 138 computer graphics 1 antipsychotic drugs 70, 82, 124, 246 concentration response 174 -, dopamine receptor affinity 70 concentration-effect relationships 131, -, serotonergic effects 70 174,212 -, serotonin receptor affinity 70 confusion 163 antipsychotic efficacy 124 cyanopindolol 9 anxiety 52 CYP2D6 199, 238 anxiolytic/antidepressant 52 - gene 199 anxiolytics 38 cytochrome P450 199 atypical antipsychotic drugs 70, 82 autoreceptors 38 Danish University Antidepressant Group azapirones 52 (DUAG) 190 debrisoquine 199,212,230,238 benzamide 70, 82, 101 delirium 163 benzodiazepine 138 delusions 131 beta-adrenergic receptors, cloning 9 depot neuroleptics 212 -, ligand binding 9 depression 131, 149 -, molecular characterization 9 -, bipolar 149 -, regulation 9 -, neurotic 149 -, structure 9 -, psychotic 149 -, subtypes 9 -, serotonin 38 beta2-adrenergic receptors -, treatment 149 biochemical basis 101 -, unipolar 149 blunted affect 131 desipramine 149, 163, 199,212,230 266 Subject Index dexamethasone test 149 genetic polymorphism 199 diagnostic heterogeneity 124 genetics 124 diazepam 199 genotypes 199 difludazine 101 genotyping 199 dopamine 1, 82 gepirone 38 - auto receptor 82 glutamate 124 - Dl receptor 1,82 - D2 receptor 1,82,94, 124, 138 hallucinations 131 - D3 receptor 82 hallucinogenic effects 52 - receptor antagonists 131 haloperidol 70, 101, 138, 199,212,230, dose binding 111 246 dose equivalency 131 Hamilton Depression Scale (HDS) 190 dose response 174 heterogeneity, schizophrenia 124 dose-effect relationship 163, 174 high pressure liquid chromatography dose-effect study 163 (HPLC) 212 drop-out 190 HVA, plasma 124 - rates 190 drug development 111 idazoxan 111 drug efficacy 124 125I-iodocyanopindolol 15 drug interaction 199 imipramine 163, 190, 199, 212, 238, 253 drug level monitoring 163 - in depression 163 drug metabolism 199 - in neuropathy pain 163 - in the elderly 238 - in nocturnal enuresis 163 drug metabolites 174 immunoassays 212 drug oxidations 199 individual dose adjustment 190 drug testing 111 interethnic differences 199,212 -, animal models 111 interindividual differences 199,230 -, physiological models 111 interindividual variability 212 drug trials 190 interrater reliability 190 drug-induced Parkinsonism 131 iodocyanopindolol 15 DSM-III 190 ipsapirone 38 DSM-I1I-R 149 isocarboxazide 149 dysthymia 149 dystonia 101 ketanserin 15

elderly 238 large ventricles schizophrenia 124 elderly population 238 levomepromazine 199,212,230,246 electroconvulsive shock 149 ligand interaction 1 extensive metabolizers (EM) 199,230, limbic system 82 238 liver insufficiency 212 extrapyramidal effects 238 low drug doses 163 extrapyramidal side effects 101 extrapyramidal syndromes 70, 94, 101 m-chlorophenylpiperazine (m-CPP) 52 extrapyramidal system 82 MAO-inhibitors 149 maprotiline 149 fixed dose 163, 190 maximal tolerated dose 111 flexible dose 163, 190 melperone 70, 101 fluoxetine 149, 199, 212, 253 mephenytoin 199,238 flupenthixol 212 mesulergine 15 fluperlapine 70 metabolic ratios 199 fluphenazine 131, 138, 163, 199,212 metabolites 174 fluspirilene 131 2-methylserotonin 70 fluvoxamine 149,174,199,253 mianserin 9, 199 fusaric acid 111 moclobemide 190, 199 molecular dynamics simulations 1 G protein 1,26,38,82 molecular electrostatic potentials 1 gas-liquid chromatography 212, 246 molecular mechanisms 1 Subject Index 267 molecular modeling 1 radioreceptor assay 212 rating scales 174 negative symptoms 131 receptor amino acid sequence 82 neuroleptic treatment 131 receptor heterogeneity 52 neuroleptics 199,212,230,246 receptor localization 26 Newcastle inventory 190 receptor mRNA 82 non-complicance 163, 190,212 receptor occupancy 70 nortriptyline 163, 190, 212 receptor ontogeny 26 receptor structure 1 obsessive-compulsive agoraphobia 149 receptors 1 obsessive compulsive disorder (OCD) 52 reduced haloperidol 212, 230 odansetron 38 remoxipride 70,82,101,199 8-0H-DPAT 38 response rate 163 orthostatism 163 reversible MAO inhibitors 190 oxprenolol 15 risperidone 101 ritanserin 15,52, 70, 101 panic disorder 52 parachlorophenylalinine (PCP A) 111 paroxetine 163, 174, 190, 199,253 s-adenosyl-methionine 111 - binding 26 s-mephenytoin 199,230 penfluridol 131 S21D2 antagonist ratio 70, 101 pergolide 82 Scale for the Assessment of Negative perphenazine 199,212,230 Symptoms (SANS) 131 pharmacogenetics 199 SCH 23390 101 pharmacokinetics 138,174 schizophrenia 82,124,131,138 phenothiazines 212, 238 - subtypes 124 phenotypes 199 sedation 163 phenotyping 163, 199 seizures 174 phospholipase C 26 selective serotonin reuptake inhibitors pimozide 70, 82, 131 (SSRI) 190 pipothiazine 82 serotonin auto receptors 38 placebo 253 serotonin receptors 1,15,38,70 plasma concentrations 246 -, cloning 15,70 plasma level monitoring 199,212,253 -, function 15 plasma levels, neuroleptics 138 -, ligand binding 15 plasma prolactin levels 70 -, molecular characterization 15 polymorphic metabolism 212 -, subtypes 15,52 poor metabolizers (PM) 199,212,230, serotonin reuptake inhibitors 38, 174, 199 238 serotonin transport 38 Positive and Negative Symptom Scale serotonin 5-HTA receptor 26 (PANSS) 131 serotonin 5-HT1A receptor 1,38,52 positive symptoms 131 serotonin 5-HTlB receptor 38,52 positron emission tomography 94, 124 serotonin 5-HT1C receptor 26, 52 post-psychotic depression 131 serotonin 5-HTm receptor 26,38,52 prediction of steady-state concentrations serotonin 5-HTlE receptor 52 212 serotonin 5-HT2 receptor 1,38,52 prolactin 124 serotonin 5-HT3 receptor 26,52 propranolol 9,38 serotonin 5-HT4 receptor 26,52 protein kinase C 111 sertraline 174, 199,253 psychomotor retardation 131 serum drug concentrations 190 publication bias 190 setoperone 101 sparteine 199,212,230 quinerolane 82 spiperone 15 quinperole 82 spontaneous recovery 163 steady-state plasma levels 230,246 raclopride 70, 101 stereospecific metabolism 212 [llC]raciopride 94 sulpiride 70,82, 101, 124 268 Subject Index tardive dyskinesia 238 type-l error 163 tefludazine 101 type-2 error 163 therapeutic drug monitoring 199,246 tyrosine transport 124 therapeutic index 174 therapeutic range 163 UH232 82 thioridazine 70, 199,212,230 underdosing 163 three-dimensional structure 1 1L99 82 voice analysis 131 toxicity 174 trazedone 253 whole blood concentrations 212 tricyclic antidepressant efficacy 149 within-patients variability 246 tricyclic antidepressants (TCA) 163,174, 190,199,212,238 zimelidine 149, 174 tryptophan hydroxylase 52 zuclopenthixol 212, 230